Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: A novel antiviral agent, remdesivir (RDV), is a promising candidate treatment for coronavirus disease 2019 (COVID-19) in the absence of any proven therapy. Materials and Methods: This retrospective case series included 10 patients with a clinically and laboratory confirmed diagnosis of severe COVID-19 pneumonia who had received RDV for 5 days (n = 5) or 10 days (n = 5) in the Phase III clinical trial of RDV (GS-US-540-5773) conducted by Gilead Sciences. The clinical and laboratory data for these patients were extracted. Results: One patient in the 10-day group received RDV for only 5 days because of nausea and elevated liver transaminases. No patient had respiratory comorbidity. Seven patients had bilateral lesions and three had unilateral lesions on imaging. All patients had received other medications for COVID-19, including lopinavir/ritonavir and hydroxychloroquine, before administration of RDV. Five patients required supplemental oxygen and one required mechanical ventilation. All patients showed clinical and laboratory evidence of improvement. Half of the patients developed elevated liver transaminases and three had nausea. There were no adverse events exceeding grade 2. Conclusion: Our experience indicates that RDV could be a therapeutic option for COVID-19. A well-designed randomized controlled clinical trial is now needed to confirm the efficacy of RDV in patients with COVID-19.
Abstract
Background: A novel antiviral agent, remdesivir (RDV), is a promising candidate treatment for coronavirus disease 2019 (COVID-19) in the absence of any proven therapy. Materials and Methods: This retrospective case series included 10 patients with a clinically and laboratory confirmed diagnosis of severe COVID-19 pneumonia who had received RDV for 5 days (n = 5) or 10 days (n = 5) in the Phase III clinical trial of RDV (GS-US-540-5773) conducted by Gilead Sciences. The clinical and laboratory data for these patients were extracted. Results: One patient in the 10-day group received RDV for only 5 days because of nausea and elevated liver transaminases. No patient had respiratory comorbidity. Seven patients had bilateral lesions and three had unilateral lesions on imaging. All patients had received other medications for COVID-19, including lopinavir/ritonavir and hydroxychloroquine, before administration of RDV. Five patients required supplemental oxygen and one required mechanical ventilation. All patients showed clinical and laboratory evidence of improvement. Half of the patients developed elevated liver transaminases and three had nausea. There were no adverse events exceeding grade 2. Conclusion: Our experience indicates that RDV could be a therapeutic option for COVID-19. A well-designed randomized controlled clinical trial is now needed to confirm the efficacy of RDV in patients with COVID-19.
참고문헌 (23)
- "Coronavirus disease 2019 (COVID-19) situation report - 101"[URL]
- "Coronavirus disease 2019 (COVID-19) domestic outbreak status"[URL]
- "Company statements: Gilead Sciences statement on the company's ongoing response to the 2019 Novel Coronavirus (2019-nCoV)"[URL]
- Agostini ML, "Coronavirus susceptibility to the antiviral remdesivir(GS-5734)is mediated by the viral polymerase and the proofreading exoribonuclease", MBio, 9, pp.e0221~e0318 (2018)
- Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
- Lescure FX, "Clinical and virological data of the first cases of COVID-19 in Europe : a case series", Lancet Infect Dis, 20, pp.697~706 (2020)
- Grein J, "Compassionate use of remdesivir for patients with severe Covid-19", N Engl J Med, 382, pp.2327~2336 (2020)
- Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
- Chen F, "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds", J Clin Virol, 31, pp.69~75 (2004)
- Chan JF, "Treatment with lopinavir", ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, 2015, pp.212, 1904~1913
- Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
- Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", Clin Infect Dis (2020)
- Rosenberg ES, "Association of treatment with hydroxychloroquine or azithromycin with in-hospital Mortality in patients with COVID-19 in New York state", JAMA, 323, pp.2493~2502 (2020)
- Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with Covid-19", N Engl J Med, 382, pp.2411~2418 (2020)
- Warren TK, "Therapeutic efficacy of the small molecule GS- 5734 against Ebola virus in rhesus monkeys", Nature, 531, pp.381~385 (2016)
- Lo MK, "GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses", Sci Rep, 7, pp.43395~ (2017)
- Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci Transl Med, 9, pp.eaal3653~ (2017)
- Elfiky AA, "Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase(RdRp) : a molecular docking study", Life Sci, 253, pp.117592~ (2020)
- Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
- Augustin M, "Remdesivir for patients with severe COVID-19", Internist(Berl), 61, pp.644~645 (2020)
- Cao YC, "Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19 : An evaluation of the evidence", Travel Med Infect Dis, 35, pp.101647~ (2020)
- Shannon A, "Remdesivir and SARS-CoV-2 : structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites", Antiviral Res, 178, pp.104793~ (2020)
- Beigel JH, "Remdesivir for the treatment of Covid-19 - preliminary report", N Engl J Med (2020)